Autoimmunity Reviews

Article	Citations
The SARS-CoV-2 as an instrumental trigger of autoimmunity	379
Rheumatoid arthritis: Extra-articular manifestations and comorbidities	224
Beyond the joints, the extra-articular manifestations in rheumatoid arthritis	175
Interleukin 1α: a comprehensive review on the role of IL-1α in the pathogenesis and treatment of autoimmune and inflammatory diseases	174
The influence of cytokines on the complex pathology of ulcerative colitis	157
Post-COVID syndrome. A case series and comprehensive review	149
SARS-CoV-2, the autoimmune virus	148
Response to SARS-CoV-2 vaccination in immune mediated inflammatory diseases: Systematic review and meta-analysis	133
An updated advance of autoantibodies in autoimmune diseases	116
CCR6-CCL20 axis as a therapeutic target for autoimmune diseases	113
An Overview of the NF-kB mechanism of pathophysiology in rheumatoid arthritis, investigation of the NF-kB ligand RANKL and related nutritional interventions	108
Dysfunctional mitochondria as critical players in the inflammation of autoimmune diseases: Potential role in Sjögren’s syndrome	105
B cell activating factor (BAFF): Structure, functions, autoimmunity and clinical implications in Systemic Lupus Erythematosus (SLE)	104
Novel insights into macrophage diversity in rheumatoid arthritis synovium	90
The autonomic aspects of the post-COVID19 syndrome	81
Rheumatological complications of Covid 19	78
The pre-clinical phase of rheumatoid arthritis: From risk factors to prevention of arthritis	74
Pathogenesis, clinical features, and treatment strategy for rheumatoid arthritis-associated interstitial lung disease	73
Role of interleukin-6 in bone destruction and bone repair in rheumatoid arthritis	71
Autoantibodies and SARS-CoV2 infection: The spectrum from association to clinical implication: Report of the 15th Dresden Symposium on Autoantibodies	64
Neuropsychiatric involvement in systemic lupus erythematosus: A review	63
The role of T cells in pemphigus vulgaris and bullous pemphigoid	62
Efficacy and safety of abatacept in interstitial lung disease of rheumatoid arthritis: A systematic literature review	61
Eosinophilic granulomatosis with polyangiitis: A review	54
Clinical outcomes of COVID-19 in patients with rheumatic diseases: A systematic review and meta-analysis of global data	54

Immunosenescence in multiple sclerosis: the identification of new therapeutic targets	53
Mucous membrane pemphigoid	52
Autoantibodies in COVID-19: frequency and function	51
Relationship between disease activity, organ damage and health-related quality of life in patients with systemic lupus erythematosus: A systemic review and meta-analysis	51
Disease modifying therapies in relapsing-remitting multiple sclerosis: A systematic review and network meta-analysis	50
Systematic review and meta-analysis of cardiovascular risk in rheumatological disease: Symptomatic and non-symptomatic events in rheumatoid arthritis and systemic lupus erythematosus	49
Eculizumab use in catastrophic antiphospholipid syndrome (CAPS): Descriptive analysis from the “CAPS Registry”	48
Autoimmune pre-disease	48
The roles of adenosine deaminase in autoimmune diseases	47
“Non-criteria” antiphospholipid syndrome: A nomenclature proposal	46
The growing role of precision medicine for the treatment of autoimmune diseases; results of a systematic review of literature and Experts’ Consensus	45
Interplay of immune and kidney resident cells in the formation of tertiary lymphoid structures in lupus nephritis	45
Seronegative autoimmune diseases: A challenging diagnosis	44
Direct oral anticoagulants in antiphospholipid syndrome: Meta-analysis of randomized controlled trials	44
Update in immunosuppressive therapy of myasthenia gravis	44
Giant cell arteritis or polymyalgia rheumatica after influenza vaccination: A study of 12 patients and a literature review	44
Pentraxin 3: A promising therapeutic target for autoimmune diseases	43
Phoenix from the flames: Rediscovering the role of the CD40–CD40L pathway in systemic lupus erythematosus and lupus nephritis	43
Autoimmunity roots of the thrombotic events after COVID-19 vaccination	42
Autoimmune/inflammatory syndrome induced by adjuvants (ASIA) in 2023	41
Combination therapy in inflammatory bowel disease – from traditional immunosuppressors towards the new paradigm of dual targeted therapy	41
Immune checkpoint inhibitors therapies in patients with cancer and preexisting autoimmune diseases: A meta-analysis of observational studies	40
Rheumatic heart disease: A review of the current status of global research activity	40
Rituximab in adult minimal change disease and focal segmental glomerulosclerosis - What is known and what is still unknown?	39
Monocytes and macrophages in ANCA-associated vasculitis	39
Hygiene hypothesis and autoimmune diseases: A narrative review of clinical evidences and mechanisms	39
The value of anti-neutrophil cytoplasmic antibodies (ANCA) testing for the diagnosis of ANCA-associated vasculitis, a systematic review and meta-analysis	39
Pregnancy outcome predictors in antiphospholipid syndrome: A systematic review and meta-analysis	39
Mesenchymal stromal cells for systemic sclerosis treatment	37
Working and safety profiles of JAK/STAT signaling inhibitors. Are these small molecules also smart?	37
Insights into new-onset autoimmune diseases after COVID-19 vaccination	36
IgA vasculitis in adult patient following vaccination by ChadOx1 nCoV-19	36
Primary Sjögren's syndrome is associated with increased risk of malignancies besides lymphoma: A systematic review and meta-analysis	36
Exosomes as biomarkers and therapeutic delivery for autoimmune diseases: Opportunities and challenges	35
Autoimmunity in dry eye disease – An updated review of evidence on effector and memory Th17 cells in disease pathogenicity	35
Antibody glycosylation in autoimmune diseases	35
The pathophysiology of polymyalgia rheumatica, small pieces of a big puzzle	35
Minor salivary gland biopsy: Its role in the classification and prognosis of Sjögren's syndrome	34
Mucosal vitamin D signaling in inflammatory bowel disease	34
JAK inhibitors and autoimmune rheumatic diseases	33
Environmental risk factors associated with ANCA associated vasculitis: A systematic mapping review	33
Engineered antigen-specific regulatory T cells for autoimmune skin conditions	33
The prevalence and incidence rate of pulmonary arterial hypertension in systemic sclerosis: Systematic review and meta-analysis	33
Endometriosis and autoimmunity: Can autoantibodies be used as a non-invasive early diagnostic tool?	33
Autoimmunity in vitiligo: Therapeutic implications and opportunities	32
Parkinson's disease is an autoimmune disease: A reappraisal	32
Emerging role of the cGAS-STING signaling pathway in autoimmune diseases: Biologic function, mechanisms and clinical prospection	32
Drug-induced IgA vasculitis in children and adults: Revisiting drug causality using a dual pharmacovigilance-based approach	32
Global burden and cross-country inequalities in autoimmune diseases from 1990 to 2019	31
Circadian clock genes as promising therapeutic targets for autoimmune diseases	31

Regulatory T cell heterogeneity and therapy in autoimmune diseases	31
Systemic autoinflammatory disease in adults	30
The revisited role of interleukin-1 alpha and beta in autoimmune and inflammatory disorders and in comorbidities	30
A proposed role of neutrophil extracellular traps and their interplay with fibroblasts in ANCA-associated vasculitis lung fibrosis	30
Overview of IgG4-related aortitis and periaortitis. A decade since their first description	30
Digital health, big data and smart technologies for the care of patients with systemic autoimmune diseases: Where do we stand?	30
Autoimmune autonomic nervous system imbalance and conditions: Chronic fatigue syndrome, fibromyalgia, silicone breast implants, COVID and post-COVID syndrome, sick building syndrome, post-orthostatic	30
JAK inhibitors and systemic sclerosis: A systematic review of the literature	29
Risk factors for hypertension in rheumatoid arthritis patients–A systematic review	29
New insight into the role of exosomes in vitiligo	28
Factors associated with fertility abnormalities in women with systemic lupus erythematosus: a systematic review and meta-analysis	28
Tumour- associated autoantibodies as prognostic cancer biomarkers- a review	28
T cell abnormalities in systemic sclerosis	28
The COVID-19 pandemic and ANCA-associated vasculitis – reports from the EUVAS meeting and EUVAS education forum	28
The biology, pathogenetic role, clinical implications, and open issues of serum anti-neutrophil cytoplasmic antibodies	27
Temporal trends in the prevalence of autoimmune diseases from 1990 to 2019	27
Global burden and risk factors of musculoskeletal disorders among adolescents and young adults in 204 countries and territories, 1990–2019	27
Antiphospholipid antibodies and thrombotic events in COVID-19 patients hospitalized in medicine ward	27
The myristoylated alanine-rich C-kinase substrates (MARCKS): A membrane-anchored mediator of the cell function	27
An updated review of anti-Ro52 (TRIM21) antibodies impact in connective tissue diseases clinical management	26
Autoimmunity and COVID-19 – The microbiotal connection	26
Rituximab for the treatment of eosinophilic granulomatosis with polyangiitis: A systematic literature review	26
JAK inhibitors and psoriatic arthritis: A systematic review and meta-analysis	26
Emerging role of Tissue Resident Memory T cells in vitiligo: From pathogenesis to therapeutics	26
Oxidative stress, mitochondrial dysfunction, and respiratory chain enzyme defects in inflammatory myopathies	26
Immune-mediated necrotizing myopathy (IMNM): A myopathological challenge	26
Follow-up of COVID-19 patients: LA is transient but other aPLs are persistent	25
Comorbidities and health-related quality of life in Patients with Antineutrophil Cytoplasmic Antibody (ANCA) - associated vasculitis	25
Significance of IL-7 and IL-7R in RA and autoimmunity	25
What can we learn from rapidly progressive interstitial lung disease related to anti-MDA5 dermatomyositis in the management of COVID-19?	25
Immune system activation in polymyalgia rheumatica: Which balance between autoinflammation and autoimmunity? A systematic review	24
Childhood-onset systemic lupus erythematosus-related antiphospholipid syndrome: A multicenter study with 1519 patients	24
Reactive oxygen species: The Yin and Yang in (auto-)immunity	24
Macrophages in Lupus Nephritis: Exploring a potential new therapeutic avenue	24
Alarmins in autoimmune diseases	24
Susac syndrome: A scoping review	24
Circulating Calprotectin (cCLP) in autoimmune diseases	23
Ocular microvascular damage in autoimmune rheumatic diseases: The pathophysiological role of the immune system	23
A machine learning analysis to predict the response to intravenous and subcutaneous immunoglobulin in inflammatory myopathies. A proposal for a future multi-omics approach in autoimmune diseases	23
Molecular mimicry between SARS-CoV-2 and human proteins	23
Molecular basis of vitamin D action in inflammatory bowel disease	22
Psoriasis: Interplay between dysbiosis and host immune system	22
Fc receptors gone wrong: A comprehensive review of their roles in autoimmune and inflammatory diseases	22
Pathophysiologic role of Interleukin-33/ST2 in Sjögren's syndrome	22
Mendelian randomization as a tool to gain insights into the mosaic causes of autoimmune diseases	22
Guillain Barré syndrome and COVID-19: Possible role of the cytokine storm	22
Effect of omega-3 fatty acids on systemic lupus erythematosus disease activity: A systematic review and meta-analysis	22
Efficacy and safety of intravenous and subcutaneous immunoglobulin therapy in idiopathic inflammatory myopathy: A systematic review and meta-analysis	22
Sexual dimorphism in immunometabolism and autoimmunity: Impact on personalized medicine	21
Primary CNS vasculitis: A systematic review on clinical characteristics associated with abnormal biopsy and angiography	21
Cytokines and intestinal epithelial permeability: A systematic review	21
The seasonality of Dermatomyositis associated with anti-MDA5 antibody: An argument for a respiratory viral trigger	21
Cancer incidence in primary Sjögren's syndrome: Data from the French hospitalization database	20
The autoimmune aetiology of unexplained chronic pain	20
Profiling and targeting connective tissue remodeling in autoimmunity - A novel paradigm for diagnosing and treating chronic diseases	20
Involvement of aquaporin 5 in Sjögren’s syndrome	20
Pharmacological treatments for SSc-ILD: Systematic review and critical appraisal of the evidence	20
Autophagy in lupus nephritis: A delicate balance between regulation and disease	20
Efficacy of immunosuppressive therapy in myocarditis: A 30-year systematic review and meta analysis	20
Eurolupus cyclophosphamide plus repeated pulses of methyl-prednisolone for the induction therapy of class III, IV and V lupus nephritis	19
Similarities between COVID-19 and systemic sclerosis early vasculopathy: A “viral” challenge for future research in scleroderma	19
COVID-19 and the antiphospholipid syndrome	19
Therapeutic mTOR blockade in systemic autoimmunity: Implications for antiviral immunity and extension of lifespan	19
Myocarditis in systemic immune-mediated diseases: Prevalence, characteristics and prognosis. A systematic review	19
Arterial stiffness, the hidden face of cardiovascular risk in autoimmune and chronic inflammatory rheumatic diseases	18
Histopathological features of systemic sclerosis-associated myopathy: A scoping review	18
Epigenetics, pregnancy and autoimmune rheumatic diseases	18
Ocular involvement in monogenic autoinflammatory disease	18
Combined Anakinra and Ruxolitinib treatment to rescue extremely ill COVID-19 patients: A pilot study.	18
New insights for regulatory T cell in lupus nephritis	18
Nutrition and its role in prevention and management of rheumatoid arthritis	18
Effect of body mass index on treatment response of biologic/targeted-synthetic DMARDs in patients with rheumatoid arthritis, psoriatic arthritis or axial spondyloarthritis. A systematic review	18
Posterior reversible encephalopathy syndrome: A neuropsychiatric manifestation of systemic lupus erythematosus	18
Undifferentiated connective tissue disease at risk for systemic sclerosis: Which patients might be labeled prescleroderma?	17
Prevention of rheumatoid arthritis: A systematic literature review of preventive strategies in at-risk individuals	17
Autoantibodies targeting G protein-coupled receptors: An evolving history in autoimmunity. Report of the 4th international symposium	17
Emerging role of galectin family in inflammatory autoimmune diseases	17
The role of TAPSE/sPAP ratio in predicting pulmonary hypertension and mortality in the systemic sclerosis EUSTAR cohort	16
Autoimmunity and cancer	16
Rare antibody-mediated and seronegative autoimmune encephalitis: An update	16

Exploring IL-17 in spondyloarthritis for development of novel treatments and biomarkers	16
Autoimmune encephalitis after herpes simplex encephalitis: A still undefined condition	16
Contemporary advances in anti-NMDAR antibody (Ab)-mediated encephalitis	16
Autoimmune polyendocrine syndrome type 1: Clinical manifestations, pathogenetic features, and management approach	16
Lymphocyte activation gene-3 (LAG-3) regulatory T cells: An evolving biomarker for treatment response in autoimmune diseases	16
Spondylitis-psoriasis-enthesitis-enterocolitis-dactylitis-uveitis-peripheral synovitis (SPEED-UP) treatment	16
ANCA and anti-glomerular basement membrane double-positive patients: A systematic review of the literature	16
Efficacy of intravenous immunoglobulin in autoimmune neurological diseases. Literature systematic review and meta-analysis	16
Granulomatous manifestations associated with COVID19 infection: Is there a link between these two diseases?	16
Inflammatory muscle involvement in systemic vasculitis: A systematic review	16
Friend or foe: RIG- I like receptors and diseases	15
Treatment of autoimmunity: The impact of disease-modifying therapies in multiple sclerosis and comorbid autoimmune disorders	15
B lymphocytes, the gastrointestinal tract and autoimmunity	15
The mosaic of autoimmunity – Finally discussing in person. The 13th international congress on autoimmunity 2022 (AUTO13) Athens	15
Antiphospholipid antibodies and the risk of autoimmune hemolytic anemia in patients with systemic lupus erythematosus: A systematic review and meta-analysis	15
The effectiveness of tocilizumab and its comparison with tumor necrosis factor alpha inhibitors for Takayasu Arteritis: A systematic review and meta-analysis	15
Epidemiology of major relapse in giant cell arteritis: A study-level meta-analysis	15
Type I Interferon as cardiovascular risk factor in systemic and cutaneous lupus erythematosus: A systematic review	15
Residual pain in rheumatoid arthritis: Is it a real problem?	15
Vasculitis therapy refines vasculitis mechanistic classification	15
Biobetters in patients with immune-mediated inflammatory disorders: An international Delphi consensus	15
Do we believe in non-radiographic axial spondyloarthritis? A debate	15
Salivary gland involvement in ANCA-associated vasculitis	15
Methotrexate in early rheumatoid arthritis: Is the anchor drug still holding?	15
Association of COVID-19 and Acute Disseminated Encephalomyelitis (ADEM) in the absence of pulmonary involvement	15